Edwards Lifesciences' Acquisition Blocked, 2026 EPS Guidance Revised Upwards

Written by Emily J. Thompson, Senior Investment Analyst

EW-0.45%

Source: NASDAQ.COM

Updated: Jan 10 2026

0mins

Source: NASDAQ.COM

Acquisition Blocked: The U.S. District Court for the District of Columbia granted the FTC's motion, effectively blocking Edwards Lifesciences' proposed acquisition of JenaValve Technology, which hinders the company's market expansion strategy.
Patient Interest Dispute: Edwards expressed disagreement with the ruling, emphasizing that the acquisition would have benefited a large, growing, and underserved patient group, highlighting the company's focus on market opportunities.
Guidance Revision: The company revised its full-year 2026 adjusted EPS guidance to a range of $2.90-$3.05, up from the previous $2.80-$2.95, indicating an optimistic outlook for future performance.
Analyst Expectations: Analysts expect Edwards to report earnings of $2.87 per share for fiscal year 2026, typically excluding special items, aligning with the company's revised guidance and reflecting market confidence in its fundamentals.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like EW with instant alerts to capture every critical market movement.

Sign up for free to build your custom watchlist and receive professional-grade stock notifications.

EW

$81.49+Infinity%1D

Analyst Views on EW

Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 96.52 USD with a low forecast of 84.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

24 Analyst Rating

16 Buy

8 Hold

0 Sell

Moderate Buy

Current: 81.860

Low

84.00

Averages

96.52

High

105.00

Current: 81.860

Low

84.00

Averages

96.52

High

105.00

Stifel

Buy

maintain

$105 -> $110

2026-01-20

Reason

Stifel

Price Target

$105 -> $110

AI Analysis

2026-01-20

maintain

Buy

Reason

Stifel raised the firm's price target on Edwards Lifesciences to $110 from $105 and keeps a Buy rating on the shares, reporting that the firm's fifty physician TAVR survey results were "highly encouraging for TAVR growth as a whole and Edwards specifically."

Piper Sandler

Overweight

maintain

$95 -> $98

2026-01-20

Reason

Piper Sandler

Price Target

$95 -> $98

2026-01-20

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Edwards Lifesciences to $98 from $95 and keeps an Overweight rating on the shares. The firm is updating a handful of its models to adjust for preliminary Q4 results and initial full year 2026 guidance announcements from this past week or so.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EW

Unlock Now

About EW

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.